Altogether, these data indicate that RNF113A is a bona fide substrate of SMYD3 in SCLC cells and suggest that the SMYD3–RNF113A signaling may participate in SCLC resistance to alkylation-based chemotherapy. This evidence concerns the gene RNF113A and small cell lung carcinoma.